Related Experiment Video
Updated: Sep 12, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Burden of Treatment-Induced Vasomotor Symptoms in Men With Prostate Cancer on Androgen-Deprivation Therapy: A
Mayank Ajmera1, Kai-Jye Lou2, Sydney Ng2
1Astellas Pharma Global Development, Northbrook, Illinois, USA.
Background:
Androgen-deprivation therapy (ADT) for prostate cancer (PCa) is associated with vasomotor symptoms (VMS; hot flashes and night sweats). However, the impact of VMS has not been well characterized. This systematic literature review analyzed patient-reported outcome (PRO) instruments used to assess the quality of life (QoL) impact of ADT-induced VMS as well as the associated humanistic burden and epidemiology.
Methods:
MEDLINE In-Progress, Embase, Cochrane Database of Systematic Reviews (2011-2024), and major oncology and health economics and outcomes research conferences (2023-2024) were searched.
Results:
In total, 52 studies were included. Of 15 PRO instruments identified, the most common were the Hot Flash-Related Daily Interference Scale, the Expanded Prostate Index Composite-26, and hot flash daily diaries. No PRO instrument was specifically validated to assess the effect of ADT-induced VMS on QoL in PCa. VMS severity (including subjective burden) was significantly associated with QoL, whereas VMS frequency was not. However, no consensus exists on VMS severity definitions. VMS negatively affected sexual functioning, interpersonal relationships, and/or work productivity, and the associated anxiety, fatigue, insomnia, and poor sleep quality were found to impair QoL. VMS additionally appeared to mediate ADT's impact on sleep disturbance. ADT-induced VMS rates ranged from 1.4% to 68.9%, with higher frequencies reported within 3-6 months of ADT initiation and when adverse events were actively monitored or participants asked to report/record VMS events (30.7%-68.9%). Lower frequencies were seen when VMS were spontaneously captured or in retrospective analyses without active VMS monitoring/reporting (1.4%-15.8%) and with enzalutamide, apalutamide, and abiraterone as add-on therapy to ADT (13.9%-15.8%).
Conclusions:
VMS severity in men with PCa is more consistently associated with QoL impact versus VMS frequency. A need for PRO instruments specific to treatment-related VMS in PCa and a lack of consensus on definitions of severity for ADT-induced VMS in PCa were identified.
Related Concept Videos
01:20Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...